Keywords

• Tofacitinib Citrate low price
• Tofacitinib Citrate manufacturer
• Hot sale Tofacitinib Citrate

Quick Details

• ProName: Hot sale Tofacitinib Citrate low price...
• CasNo: 540737-29-9
• Molecular Formula: C16H20N6O·C6H8O7
• Appearance: white powder
• Application: cas：540737-29-9
• DeliveryTime: ship immediately after confirmation.
• PackAge: According to your demand
• Port: any port in China
• ProductionCapacity: Metric Ton/Day
• Purity: 98%
• Transportation: as requested
• LimitNum: 0 Metric Ton
• Grade: Pharma Grade

Superiority

Hot sale Tofacitinib Citrate low price manufacturer

Tofacitinib citrate is a king of drugs developed by the US pharmaceutical company Pfizer for treating rheumatoid arthritis, trade name Xeljanz, for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid arthritis (RA) in adult patients. This product is a Janus kinase inhibitor, administered twice daily.
November 6, 2012, the US Food and Drug Administration (FDA) and Pfizer jointly announced Tofacitinib citrate is approved for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid joints arthritis (RA) in adult patients.
Xeljanz can be used as monotherapy or in combination with methotrexate or other non-biological disease-modifying antirheumatic drugs (the DMARD) in combination. This medicine should not be in combination with biological DMARD or strong immunosuppressants (such as cyclosporine and azathioprine). Xeljanz is approved by the daily dose of 2 times, each time 5mg.
Seven clinical trials evaluated the safety and efficacy of Tofacitinib citrate in moderate to severe active RA in adult patients. In all tests, compared with patients receiving placebo, patients receiving Xeljanz treatment showed significant improvement in clinical response and physical function.
In Clinical trials, the most common adverse events were upper respiratory tract infection, headache, diarrhea, nasal congestion, sore throat, and nasopharyngitis.
Using Xeljanz was associated with an increased risk of serious infections, including opportunistic infections, tuberculosis, cancer and lymphoma. Xeljanz product label attaches boxed warning on these security risks. Xeljanz treatment is also associated with reducing blood cell counts and increasing cholesterol and liver enzyme values.
In order to study Xeljanz long-term impact on heart disease, cancer and severe infections, FDA requires for a post-marketing study, which will evaluate two doses of Xeljanz (Tofacitinib citrate) therapy, and accept a integration of another group of patients approved by the treatment as a control.

Potent, cell-permeable inhibitor of JAK1/2/3 (in cell-free assays JAK1 IC₅₀ = 112 nM; JAK2 IC₅₀ = 20 nM; JAK3 IC₅₀ = 1 nM). Exhibits immunosuppressive, anti-inflammatory, and antiviral activities. Inhibits production of inflammatory cytokines, Th2 cell differentiation, Th17 cell differentiation, and activation of STAT1 in vitro. Prevents induction of T-bet and generation of Th1 cells. Inhibits HIV replication and reactivation of latent HIV-1 in cell models.

Details

Tofacitinib citrate, also known as CP-690550 citrate, is a potent inhibitor of janus kinase 3 (JAK3), a hematopoetic cell-restricted tyrosine kinase involved in signal transduction regulating lymphocyte survival, proliferation, differentiation, and apoptosis.  The inhibition is JAK3 specific with a selectivity 1000-fold more than other non-JAK family kinases. Besides inhibiting JAKS (IC50 = 1 nM), tofacitinib citrate also inhibits janus kinase 2 (JAK2) and janus kinase 1 (JAK1) with 20- and 100-fold less in potency respectively. However, in a recent study, the binding affinities (Ki) of tofacitinib citrate towards JAK1, JAK2, and JAK3 were reported to be 1.6 nM, 21.7 nM, and 6.5 nM respectively.